BioSpace News Archive

Research and science are essential to creating opportunity for Canadians and finding solutions to the challenges of today and tomorrow. That’s why the Government of Canada has committed more than $10 billion since 2016 to fund research and science, and it is why research and science have guided our response to the COVID-19 pandemic.

The U.S. Food and Drug Administration alerted consumers, health care providers and other users of thermal imaging systems intended to measure human body temperature—also known as telethermographic systems, infrared thermographs, thermal cameras, and “fever cameras"—that improper use of the systems may provide inaccurate temperature readings due to a variety of factors.

Brii Biosciences, a multi-national company developing innovative therapies for diseases with significant unmet medical needs and with a high public health impact, announced that its antibodies BRII-196 and BRII-198 failed to meet pre-specified efficacy criteria permitting expansion into the Phase 3 component of ACTIV-3.

While COVID-19 vaccines are being administered in hopes of reducing the impact of the pandemic, novel variants of SARS-CoV-2, the virus that causes COVID-19, are spreading at accelerated rates.

Companies will combine their unique scientific and technical expertise to develop a first-in-class anti-SIRPα antibody conjugated to TLR9 agonist (“SIRPα TRAAC”) that delivers targeted immune activation

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, announced that it will report fourth quarter and full year 2020 financial and operating results on Tuesday, March 16, 2021.

Fulgent Genetics, Inc., a technology company providing large-scale COVID-19 testing services and comprehensive testing solutions through its scalable technology platform, announced financial results for its fourth quarter and full year ended December 31, 2020.

T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens, announced financial results for the fourth quarter and full year ended December 31, 2020.

Kadmon Holdings, Inc. provided a business update and reported financial and operational results for the fourth quarter and full year ended December 31, 2020.

Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will release its year-end 2020 financial results on Thursday, March 11, 2021